Eris soars 11% on Thursday, zooms 61% from low; is it time to book profit?

Share price of Eris Lifesciences today
Shares of Eris Lifesciences hit a new high of ₹1,909.55, surging 11 per cent on the BSE in Thursday's intra-day trade in an otherwise weak market. The stock of this pharmaceutical company was trading higher for the third straight day, soaring 17 per cent during the period. It has bounced back 61 per cent from its April month low of ₹1,187.10 on the BSE.
At 02:13 PM; Eris was quoting 3 per cent higher at ₹1,777, as compared to 1.1 per cent decline in the BSE Sensex. The average trading volumes at the counter jumped multiple-fold with a combined 2.92 million shares changing hands on the NSE and BSE.
Is it time to book profit in Eris Lifesciences?
Currently, Eris trades above PL Capital's target price of ₹1,740 per share. Post March 2025 quarter (Q4FY25) earnings, the brokerage firm on May 20, 2025 had recommended a 'Buy' rating on Eris.
The company has multiple growth levers such as broad-based offerings in the derma segment, tapping Glucagon-like peptide 1 (GLP-1) market, demand supply mismatch in insulin segment, creating large injectable franchise across India and Rest of the World (RoW) market and benefits of operating leverage, as revenue scales up from these acquisitions, the brokerage firm said.
Eris guided for a 15 per cent organic year-on-year (YoY) growth to reach ₹2,900-₹3,000 crore in revenue in FY26. The EBITDA margin in this business is expected to be 37 per cent (+50bp YoY as per cent of sales). Eris indicated Swiss Parenterals business to the tune of ₹380 crore-₹390 crore (growth of 15-20 per cent YoY) with an EBITDA margin of 35 per cent for FY26. It targeted a net debt of ₹1,800 crore at the end of FY26 vs. ₹2,200 crore at the end of FY25.
During FY24-25, Eris progressed to secure building blocks in the Diabetes/ Obesity treatment through achieving regulatory milestones, building in-house capacity for manufacturing, and enhancing its marketing reach. Further, it is building capacity and is in the process of getting relevant regulatory approvals for international business in the injectable segment. Considering these factors and the reduction in financial leverage, Motilal Oswal Financial Services estimate a 15 per cent/17 per cent/44 per cent CAGR in sales/EBITDA/PAT over FY25-27. The brokerage firm in the Q4 results update said that they reiterate 'Neutral' rating on Eris with a target price of ₹1,350 per share.
Meanwhile, India Ratings and Research (Ind-Ra) expects the scale of operations to remain healthy and EBITDA margins to be steady in the medium term, with benefits emanating from the backward integration initiatives. Also, Ind-Ra remains positive on the recent acquisitions/initiatives in the biologics/glucagon-like peptide space albeit with contribution likely to be playing out FY27/FY28 onwards. Ind-Ra believes the chronic therapy portfolio typically has seen higher stickiness among patients, leading to higher profitability in the long term.
Ind-Ra expects the net leverage to have reduced below 2.5x during FY25 and will reduce further to 2.0x in FY26, in the absence of acquisition-led debt. The improvement in credit metrics will be supported by robust operating profitability led by integration benefits in lieu of recent acquisitions.
'
About Eris Lifesciences
Eris, a 100 per cent domestic formulation (DF) company, was established in 2007. The company focuses on the branded generics business in the chronic (87 per cent of sales) and acute segments (13 per cent of sales). The company has drugs across therapies such as anti-diabetes, cardiovascular, dermatology, gastroenterology and gynaecology, anti-infectives, vitamins, and other therapeutic areas.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Hans India

40 minutes ago

• Hans India

HDB sets IPO price band at Rs 700-740

New Delhi: HDB Financial Services, a subsidiary of HDFC Bank, on Friday fixed a price band of Rs 700-740 per share for its Rs 12,500 crore company is expected to list on the BSE and NSE on July 2. At the upper end of the price band, the company is valued at nearly Rs 61,400 crore. HDB Financial Services' maiden public issue will open for subscription on June 25 and conclude on June 27, while the bidding for the anchor investor will open for a day on June 24, the company announced. The IPO is a combination of a fresh issue of equity shares worth Rs 2,500 crore and an Offer For Sale (OFS) of Rs 10,000 crore by promoter HDFC Bank. At present, HDFC Bank holds a 94.36 per cent stake in HDB Financial Services, a non-banking financial company (NBFC) arm of the bank. The company proposes to utilise the proceeds from the fresh issue to strengthen its Tier-I capital base. This will support future capital needs, including additional lending, to support business growth. The decision to list HDB Financial Services follows the Reserve Bank of India's mandate in October 2022, requiring NBFCs in the upper layer to list on the stock exchanges within three years. Last year, HDFC Bank's board approved a share sale worth Rs 12,500 crore, comprising Rs 10,000 crore OFS related to HDB Financial Services. After the proposed IPO, HDB Financial Services will continue to be a subsidiary of the bank, in compliance with the provisions of the applicable regulations. Half of the issue size has been reserved for qualified institutional buyers, 35 per cent for retail investors and the remaining 15 per cent for non-institutional investors.

Time of India

6 hours ago

• Time of India

RBI guidelines for project finance, CRE: A smaller provisions hike's no big worry for banks, NBFCs

MUMBAI: Central bank guidelines on provisions for project finance and commercial real estate (CRE) might have only a small and negligible profitability impact on both banks and NBFCs , as the increase in immediate liabilities is less than a percentage point from those existing rules - even in the worst-case scenario. Financial and banking stocks surged on Friday. Bankers and analysts, who had pencilled in up to a 150-basis point impact on return on assets (RoAs) for lenders, now expect no new provisioning requirements as NBFCs are already on the more stringent Ind-AS accounting norms while for banks the impact is small. One basis point is 0.01 percentage point. Karthik Srinivasan , group head, financial sector ratings at ICRA said with no retrospective provisions and peak provisions much below the 5% proposed in the draft guidelines, there will be a minimal impact on lenders. "Although we are yet to create a hypothesis and do a study on the impact, it is nothing like the 150 basis points on RoA basis we had predicted earlier. We do not expect any real impact on banks or NBFCs," Srinivasan said. ICRA had earlier expected the annual impact on RoA at 100-150 bps for lenders, with funding costs going up by 20-40 bps. Both these issues will not arise as in the final guidelines general provisions required for CRE, CRE-RH (CRE-Residential Housing) and other infrastructure projects have been reduced to between 1% and 1.25% in the construction phase from a peak of 5% in the draft guidelines. Live Events Financials Surge The Nifty financial index surged 1.3%, and financial stocks were at the forefront of the stellar Nifty 50 rebound Friday from a sharp sell-off Thursday. HDFC Bank , the biggest lender by market value, climbed 1.44%, while Bajaj Housing Finance too climbed 1.4%. Provisions for projects in the operational phase have also been reduced to between 0.40% and 1%, with operational infrastructure project provisions kept at 0.40%, the same as it is currently. The new guidelines will come into force from October 1. Rajkiran Rai , managing director at infrastructure financier NaBFID, said the final guidelines limit his firm's provision increase to just 5 basis points. "If we were pricing a loan at 8%, now we will price it at 8.05%. This would have increased to 9.50% if the original guidelines had remained, so this is a big relief. The new norms also have clauses saying at least 50% to 75% of the land must be acquired for the loan to be sanctioned. This could delay loan sanctions but it will bring uniformity in application since different projects were so far treated differently on land acquisition," Rai said. For loans on infrastructure projects which have been delayed beyond three years from the date of commencement of commercial operations (DCCO), lenders have to make an additional provision of 0.375% and a 0.5625% provision on non-infrastructure project loans (including CRE and CRE-RH), for each quarter of deferment, over and above the applicable standard asset provision. "Provisioning requirement for projects beyond DCCO up to two years will go up to 4% vis-a-vis original guidelines where provision was only 0.4%," said an analyst. "Now, within DCCO, the first quarter itself will attract higher provision."

Business Standard

7 hours ago

• Business Standard

CAPE fear: History suggests rich valuations precede sharp pullbacks

Valuations at current levels have historically corresponded single-digit returns premium Sachin P Mampatta Mumbai Listen to This Article Notwithstanding indices being lower than the all-time high levels touched nine months ago, the stock market has rarely been as expensive as it is now on one particular metric. The 10-year cyclically adjusted price-to-earnings (CAPE) ratio for the BSE Sensex is at 35.2x, according to data based on a study, Forecast or Fallacy? Shiller's CAPE: Market and Style Factor Forward Returns in Indian Equities, authored originally in July 2024 by Joshy Jacob, professor at the Indian Institute of Management, Ahmedabad, and Rajan Raju, director at Singapore-based family office Invespar. The numbers are updated monthly. The latest valuations for May 2025